Edigene, A Global Biotechnology Company Focused On Translating Gene-Editing Technologies Into Transformative Therapies For Patients With Serious Genetic Diseases And Cancer, Announced A Research And Development Collaboration With Haihe Laboratory Of Cell Ecosystem To Develop Hematopoietic Stem Cell Regenerative Therapies And Platform Technology By Combining Resources And Expertise From Both Sides.The Haihe Laboratory Of Cell Ecosystem, Run By The Institute Of Hematology And Blood Diseases Hospital, Chinese Academy Of Medical Sciences And Peking Union Medical College, Is Focused On Conducting Fundamental Research, Innovation, And Translation In The Cell Ecosystem.Under The Agreement, Both Parties Will Jointly Develop Hematopoietic Stem Cell Regenerative Therapies, Including The Development Of Innovative Genetically-Modified Hematopoietic Stem Cell Therapies And The Exploration Of Novel Biomarkers To Optimize Quality Control For Stem Cell Production.
